Severe Asthma: From Bench to Bedside
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 113
Special Issue Editors
Interests: P.F.Test in asthma & COPD; biologics in severe asthma; rehabilitation and oxigen therapy in COPD
Special Issue Information
Dear Colleagues,
Biologics have proven efficient for treating T2 Severe Asthma, and biologic therapies improve patients’ quality of life of patients far more than was observable in RCTs.
With the implementation of these treatments, new questions have arisen. Can biologics temporarily or permanently modify the immunologic pattern of patients? How much do we know about eosinophils in the blood vs. those in the tissues? When we try to define absent vs. partial vs. complete response to biological therapies, do we refer to a clinical, or laboratory tool (or both)? Once we have identified the best treatment method (IL5, for example), how do the others contribute toward downregulation or compensative upregulation? Can the Pulmonary Function Test be used to stratify severe asthmatic patients? In the relatively small cohort of not T2 Severe Asthma, when do we expect to discover effective new therapeutical agents? Do the nose and bronchi always show similar responses to Biologics?
While we do not expect to resolve all of these questions in this Special Issue, we hope to explore these and other topics related to Severe Asthma from both theoretical and clinical perspectives.
Dr. Marco Bonavia
Prof. Dr. Manlio Milanese
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- asthma T2
- biologic therapies
- pulmonary function tests in asthma
- super responder
- switch therapy
- nose and bronchi
